Saturday, July 11, 2026

Drug profile · INN

sacituzumab govitecan

sacituzumab govitecan (TRODELVY) is a dna topoisomerase i inhibitor. Associated with Gilead Sciences Pty Limited.

EMA: approved TGA: approved Antineoplastic and immunomodulating agents (L01) L01FX06
Patents linked 0
Pipeline programs 14
News articles 3
Drug details — sacituzumab govitecan

Quick answer

sacituzumab govitecan (TRODELVY) is a dna topoisomerase i inhibitor. Associated with Gilead Sciences Pty Limited.

Key facts

INN sacituzumab govitecan
Brand TRODELVY
Mechanism DNA topoisomerase I inhibitor
Target DNA topoisomerase 1
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01FX06

Mechanism of action

DNA topoisomerase I inhibitor

Primary target: DNA topoisomerase 1

Approval history

Authority Status Date
EMA approved
TGA approved

Recent coverage

Pipeline programs

  1. GS-US-577-6153 Phase 3 · Gilead Sciences · Non-small cell lung cancer
  2. GS-US-592-6173 Phase 3 · Gilead Sciences · PD-L1 Positive Metastatic Triple-Negative Breast Cancer
  3. GS-US-592-6238 Phase 3 · Gilead Sciences · PD-L1-negative metastatic triple-negative breast cancer or P
  4. GS-US-595-6184 Phase 3 · Gilead Sciences · Triple Negative Breast Cancer
  5. GS-US-600-6165 Phase 3 · Gilead Sciences · Extensive Stage Small Cell Lung Cancer (ES-SCLC)
  6. GS-US-682-6769 Phase 3 · Gilead Sciences · Recurrent or Persistent Endometrial Cancer
  7. IMMU-132-13 Phase 3 · Gilead Sciences · Locally Advanced or Metastatic Unresectable Urothelial Cance
  8. Sacituzumab Govitecan-hziy Phase 3 · Gilead Sciences Ireland · Triple Negative Breast Cancer

Related & competitor drugs

  1. abiraterone acetate Antineoplastic and immunomodulating agents (L02)
  2. anagrelide Antineoplastic and immunomodulating agents (L01)
  3. apremilast Antineoplastic and immunomodulating agents (L04)
  4. arsenic trioxide Antineoplastic and immunomodulating agents (L01)
  5. axitinib Antineoplastic and immunomodulating agents (L01)
  6. azacitidine Antineoplastic and immunomodulating agents (L01)

Frequently asked questions

What is sacituzumab govitecan?

sacituzumab govitecan (TRODELVY) is a dna topoisomerase i inhibitor. Associated with Gilead Sciences Pty Limited.

What is the brand name for sacituzumab govitecan?

TRODELVY is a marketed brand name for sacituzumab govitecan. Check FDA Drugs@FDA for the current US label holder and prescribing information.